Dr. Link has served as a member of our Board since November 2016 and has served as a member of the Compensation Committee from November 2016 to July 2021 and as a member of the Audit Committee from July 2021 to February 2024. Dr. Link formed Flying L Management, LLC in 2017 and is the Managing Partner. Dr. Link has served as a managing director and cofounder of Versant Ventures Management LLC, a venture capital firm investing in early stage healthcare companies, since 1999. He has served as a member of the board of directors of Horizon Surgical since May 2024, Praxis Management, LLC since 2022, Lensar, Inc. since November 2017, and Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) since January 2017. Dr. Link also currently serves on the boards of directors of Allegro Ophthalmics, LLC, Forsight Vision 6, TearClear Corp., ViaLase, Inc., Osanni Bio, Inc. and EyeDura, Inc. Prior to co-founding Versant Ventures in November 1999. Dr. Link was a general partner at Brentwood Venture Capital from 1998 to 2020. From March 1986 to December 1997, Dr. Link was founder, chairman, and chief executive officer of Chiron Vision Corp. He also founded and served as President of American Medical Optics, Inc. (AMO) a division of American Hospital Supply Corporation, (acquired by Allergan, Inc., which was acquired by AbbVie (NYSE:ABBV) from 1978 to 1985. Dr. Link served as a director of Advanced Medical Optics, Inc. from September 2002 to February 2009, a director of Inogen, Inc. (NASDAQ:INGN) from July 2003 to February 2014, a director of Second Sight Medical Products, Inc. from August 2003 to May 2020, a director of Edwards Lifesciences Corp. (NYSE:EW) from May 2009 to May 2021, a director of Glaukos, Inc. (NYSE:GKOS) from June 2001 to December 2021, and a director of Oyster Point Pharma, Inc. (acquired by Viatris Inc. (NASDAQ:VTRS) from July 2015 to March 2022. Dr. Link also served as an assistant professor in the Department of Surgery at the Indiana University School of Medicine from 1973 to 1976. Dr. Link received a B.S., M.S., and a Ph.D. in mechanical engineering from Purdue University.
What is William J. Link's net worth?
The estimated net worth of William J. Link is at least $341,411.84 as of February 1st, 2024. Link owns 24,248 shares of RxSight stock worth more than $341,412 as of April 13th. This net worth evaluation does not reflect any other assets that Link may own. Learn More about William J. Link's net worth.
How do I contact William J. Link?
Has William J. Link been buying or selling shares of RxSight?
William J. Link has not been actively trading shares of RxSight within the last three months. Most recently, William J. Phd Link sold 28,250 shares of the business's stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $49.67, for a transaction totalling $1,403,177.50. Following the completion of the sale, the director now directly owns 24,248 shares of the company's stock, valued at $1,204,398.16. Learn More on William J. Link's trading history.
Who are RxSight's active insiders?
RxSight's insider roster includes Julie Andrews (Director), Juliet Bakker (Director), Jesse Corley (Director), Tamara Fountain (Director), Ilya Goldshleger (Insider), Ilya Goldshleger (Insider), M Kurtz (CEO), William Link (Director), Shweta Maniar (Director), Shelley Thunen (CFO), Robert Warner (Director), and Eric Weinberg (Insider). Learn More on RxSight's active insiders.
Are insiders buying or selling shares of RxSight?
In the last year, RxSight insiders bought shares 2 times. They purchased a total of 12,554 shares worth more than $549,098.81. In the last year, insiders at the sold shares 28 times. They sold a total of 160,951 shares worth more than $8,269,376.44. The most recent insider tranaction occured on March, 12th when Director Tamara Fountain sold 7,000 shares worth more than $179,970.00. Insiders at RxSight own 9.4% of the company.
Learn More about insider trades at RxSight. Information on this page was last updated on 3/12/2025.
